Market Overview:
The Europe facial injectable market size is expected to reach USD 7.33 billion by 2032, exhibiting the CAGR of 10.9% during the forecast period.
Facial injectables are a type of cosmetic therapy provided through injections to enhance facial appearance. These injectables generally contain substances such as dermal fillers, neurotoxins, and collagen stimulators. Each kind of injectable performs a specific objective in improving and extending facial aesthetics. These injectables add smoothness and volume to the skin, usually hyaluronic acid, a substance naturally constructed by the body that reduces as we age.
Also, when injected, these fillers can smooth wrinkles, plump up the skin, and give your face a more younger appearance. This is expanding the Europe facial injectable market demand.
Top Companies:
In the highly competitive European facial injectable industry, there are major and minor competitors. Businesses compete based on effectiveness, cost, new developments in the field, and customized treatment alternatives. Here are some of the top companies in the Europe facial injectable market:
Some of the major players operating in the European market include:
- Abbvie (U.S.)
- Galderma (Switzerland)
- Ispen (France)
- Merz GmbH and Co. KGaA (Germany)
- Revance Therapeutics, Inc. (U.S.)
- Sinclair Pharma (UK)
- Teoxane (Switzerland)
- Zimmer Aesthetics (Germany)
Growth Factors:
The region’s fast rise in facial injectables is mostly due to the growing desire for nonsurgical procedures. Compared to surgical alternatives, nonsurgical therapies require less recovery time. Also, the lower price of nonsurgical alternatives is another influencing aspect that will help surge the demand for facial injectables.
Moreover, advancements in injectable technologies have resulted in the creation of improved formulations with improved qualities through ongoing research and development. Treatment frequency is being reduced as a result of new delivery routes and injectable technologies that produce more consistent results.
Europe Facial Injectable Market, Countries Outlook (Revenue – USD Million, 2019-2032)
- Germany
- Product Outlook
- Collagen & PMMA Microspheres
- Botulinum Toxin Type A
- Hyaluronic Acid (HA)
- Calcium Hydroxylapatite (CaHA)
- Poly-L-lactic Acid (PLLA)
- Others
- Application Outlook
- Facial Line Correction
- Lip Augmentation
- Face Lift
- Acne Scar Treatment
- Lipoatrophy Treatment
- Others
- End-Use Outlook
- MedSpa
- Dermatology Clinics
- Hospitals
- Product Outlook
- UK
- Product Outlook
- Collagen & PMMA Microspheres
- Botulinum Toxin Type A
- Hyaluronic Acid (HA)
- Calcium Hydroxylapatite (CaHA)
- Poly-L-lactic Acid (PLLA)
- Others
- Product Outlook
Recent Developments:
- Sinclair and ATGC Collaboration (October 2023)
Sinclair entered a global license agreement with ATGC to develop and commercialize ATGC-110, a purified botulinum toxin product aimed at treating frown lines. This partnership underscores Sinclair’s focus on expanding its portfolio in the aesthetics market. - Allergan Aesthetics Phase III Clinical Results (October 2023)
Allergan Aesthetics reported positive results from two Phase III clinical studies of treni-botulinum toxin E (BoNT/E) for treating moderate to severe glabellar lines. The results highlight the potential of BoNT/E as an innovative treatment option in aesthetic medicine.
Market expansion is due to an increase in awareness related to the benefits of facial injectables, innovation in facial injectables, and investments in the aesthetic industry. As individuals age, they experience various changes in their facial appearance, such as the development of wrinkles, fine lines, volume loss, and sagging skin. Facial injectables offer non-surgical solutions to address these signs of aging, providing patients with rejuvenated skin. As a result, the aging population is an additional factor driving the facial injectable market growth across European countries.